ATRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Atara Biotherapeutics Inc (ATRA) is not a strong buy for a beginner investor with a long-term strategy at this time. While there are some positive catalysts, such as the potential FDA approval for tab-cel and recent analyst upgrades, the technical indicators, insider and hedge fund selling trends, and lack of recent proprietary trading signals suggest caution. The stock may be better suited for monitoring rather than immediate investment.
The MACD histogram is negative and contracting, indicating bearish momentum. RSI is neutral at 54.401, and moving averages are converging, showing no clear trend. Key support and resistance levels are Pivot: 10.044, R1: 10.724, S1: 9.364, R2: 11.144, S2: 8.944.
FDA meeting for tab-cel ended positively, increasing the likelihood of U.S. approval.
Analyst upgrades with increased price targets (Freedom Broker to Hold with a $10 target, Canaccord to Buy with a $13 target).
Appointment of Brian Cherry to the Board, expected to enhance strategic capital allocation.
Significant insider selling, with a 29504.54% increase over the last month.
Hedge funds are selling, with a 192.53% increase in selling activity over the last quarter.
Post-market price decline of -0.60%.
No financial data available for the latest quarter.
Recent upgrades from Freedom Broker and Canaccord reflect optimism about tab-cel's approval pathway and potential milestone payments. Price targets have been raised to $10 and $13, respectively, indicating moderate upside potential.
